Scientific Publications Communicate product value messages through credible scientific publications. Leverage our experience Xcenda exhibits a strong publication track record, with well over 300 published manuscripts in peer-reviewed journals and more than 700 poster presentations and symposia at national conferences. We have developed publication strategies across multiple therapeutic areas, including: Infectious disease Cardiovascular/metabolic CNS/neuropsychiatry Oncology Urology Gastrointestinal Orphan disease states Highlights of our recent work Parker K, Zagadailov E, Bruno A, Wiland A. Transplant coordinators’ perceived impact of availability of multiple generic immunosuppression therapies on patients, workload, and posttransplant maintenance therapy. J of Trans. (2013)1-7 Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatement patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Ben. 2012 Sep/Oct:5(6)347-357. Lee CT, Barocas D, Globe DR, Oefelein MG, Colayco DC, Bruno A, O'Day K, Bramley T. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J Urol. 2012 Dec;188(6):2114-9. doi: 10.1016/j.juro.2012.08.005. Epub 2012 Oct 18. Eaddy M, Seal B, Tangirala K, Davies E, O’Day K. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome. Appl Health Econ Health Policy. 2012:10(6):431-440. Ye X, Rupnow M, Hammond J, Shah M, Farrelly E. Readmission rates and hospital costs associated with fibrin sealant use among patients undergoing orthopedic surgery. J. Orthopaedics. 2012;9(1)e11. Miller R, Happe L, Meyer K, Spear R. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. JMCP. 2012 Jan/Feb;18(1):54-62. Chatterjee A, Shah M, D'Souza AO, Bechtel B, Crater G, Dalal AA. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir Res. 2012 Feb 17;13(1):15. Dupclay L, Eaddy M, Jackson J, Raju A, Shim A. Real-world impact of reminder packaging on antihypertensive treatment adherence and persistence. Patient Prefer Adherence. 2012;6:499-507.Tanner N, Gomez M, Rainwater C, Nietert P, Simon G, Green M, Silvestri G. Physician preferences for management of patients with stage IIIA NSCLC, impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012 Feb;7(2):365-369. Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011 Nov 20;29(33):4436-4441. O'Day K, Meyer K, Miller R, Agarwal S, Franklin M. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ. Posted online 2011 July 22;617-627. Mauceri E, Bienkowski C, Hanson K, Doyle JJ, Jackson J, Bramer S. A health outcome assessment of the cardio metabolic mission health program at Novartis. J Occup Environ Med. 2011 Jun;53(6):647-652. Waters H, Vanderpoel J, Nejadnik B, Lunacsek O, Lennert B, Goff J, Augustyn D, McKenzie S. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. J Med Econ. 2012;15(1):45-52. Dalal A, Shah M, Lunacsek O, Hanania N. Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD. 2011;8:293-299. Pettaway C, Lamerato L, Eaddy M, Edwards J, Hogue S, Crane M. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. BJU Int. 2011;108(8):1302-8. Our citation archive includes peer-reviewed articles and posters presented at national and international conferences. From publication strategy to medical writing, we can help Turn to Xcenda and gain from a long history of publication planning, highly trained clinical staff, and expertise in both payer marketing and health economics. As your strategic partner, we'll optimize your messaging for the managed care audience, conduct additional HEOR research, and develop subsequent publications to further support and enhance your product's value proposition. Access advisors for strategic partnerships Xcenda's clients benefit from quick access to health economics KOLs from across the globe, payer decision makers from all key US segments, and leading US oncologists and hematologists. Using online surveys, live meetings, or one-on-one interviews, Xcenda conducts evidence and message testing to ensure our clients' publications resonate with payers and providers. These capabilities are key differentiators for Xcenda and allow us to deliver more value as a truly strategic partner for our clients.